ENTA
Enanta Pharmaceuticals Inc
NASDAQ · Biotechnology
$13.51
+0.54 (+4.16%)
Open$13.22
Previous Close$12.97
Day High$13.62
Day Low$13.22
52W High$17.15
52W Low$4.09
Volume—
Avg Volume173.7K
Market Cap392.04M
P/E Ratio—
EPS$-3.84
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+229.8% upside
Current
$13.51
$13.51
Target
$44.55
$44.55
$33.16
$44.55 avg
$53.28
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 88.85M | 97.45M | 82.68M |
| Net Income | -111,375,994 | -109,946,687 | -22,888,047 |
| Profit Margin | -125.4% | -119.1% | -27.7% |
| EBITDA | -109,843,816 | -114,458,292 | -23,098,769 |
| Free Cash Flow | — | — | -13,628,189 |
| Rev Growth | -8.8% | -8.8% | -7.4% |
| Debt/Equity | 2.21 | 2.21 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |